AQR Capital Management LLC bought a new position in shares of Omeros Co. (NASDAQ:OMER – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,800 shares of the biopharmaceutical company’s stock, valued at approximately $105,000.
A number of other hedge funds also recently bought and sold shares of the stock. Rhumbline Advisers lifted its holdings in Omeros by 6.1% during the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after buying an additional 6,435 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after purchasing an additional 31,081 shares during the last quarter. Cypress Capital Group lifted its holdings in shares of Omeros by 40.0% during the 2nd quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 10,000 shares during the last quarter. Comerica Bank lifted its holdings in shares of Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Omeros by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock valued at $11,213,000 after purchasing an additional 81,348 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.
Omeros Trading Up 0.2 %
Shares of OMER opened at $4.15 on Friday. Omeros Co. has a 12 month low of $1.05 and a 12 month high of $5.68. The stock has a fifty day moving average price of $3.98 and a 200-day moving average price of $3.93.
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a report on Friday, August 16th.
Read Our Latest Research Report on OMER
Omeros Company Profile
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Featured Stories
- Five stocks we like better than Omeros
- What Are Trending Stocks? Trending Stocks Explained
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Stock Dividend Cuts Happen Are You Ready?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- 10 Best Airline Stocks to Buy
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.